Tuesday, January 10, 2017 12:56:16 AM
It looks like the NR patent-holder's (Charles Brenner) student's (Samuel Trammell) U of Iowa PhD thesis sheds some light on the issue in mouse livers in Chapter 5, recently published in Nature Communications here:
http://www.nature.com/articles/ncomms12948
185 mg/kg NR was given to mice orally (7 doses over 12 hours), along with equimolar doses of NA and NAM. Figure 5b shows that NR increased mouse liver NAD+ levels with an AUC of ~16,000, significantly more than NA (AUC ~8,000) and slightly more (not significantly so) as NAM (AUC ~14,000).
One could perhaps conclude that in mice, NR is 2x as effective at increasing liver NAD+ vs NA, and ~15% more effective than NAM. In general, mice started with around ~1 mM NAD+. This increased to ~2 mM NAD+ with NA, a peak of ~3 mM NAD+ with NAM, and to >4 mM NAD+ peak with NR.
It's interesting that NR did not increase NAD+ levels significantly in the mouse heart (but it did increase NMN and NAM in heart).
They used a mouse dose of 185 mg/kg to match approximately the human dose given - 1000 mg (to a 66.5 kg, 52 yo male - Dr. Brenner? born in 1961), using mouse to human conversion factor of 12.3 based on BSA.
Apparently recommended daily dose of Vitamin B3 as NA or NAM is 15 mg /day to prevent pellagra. They say the equivalent dose of NR would be 35.7 mg (not sure on that conversion). The study tested humans with 100, 300, or 1000 mg doses of NR, and measured NAD+ increases in human blood cells (N=12). Figure 8b shows that NR increased concentrations from ~12 uM to slightly above that, say ~16 uM at 100 mg, and to ~18 uM at 300 or 1000 mg. Quantitatively, the NAD+ increase was dose dependent, with huge amount of variability between subjects.
I believe the larger Elysium study (N=120, 10x larger) showed that 250 mg/day supplementation in 60-80 year olds increased blood NAD+ levels 40% and 500 mg/day 80% over 4-8 weeks. Look forward to seeing the details published.
Would love to see the comparison of NA, NAM, and NR in humans in terms of increase in NAD+ in blood and perhaps muscle biopsy (with effects on mitochondrial number). I would be really interested to know what are the NAD+ levels in brain, heart, muscle, blood, and CSF.
One thing to keep in mind is that if NA is 10 times cheaper for equivalent dose of NR, does it really matter if NA is only 1/2 as potent? It would still be 5x better value for increase in NAD+.
There are benefits to avoiding the flushing, for sure. Perhaps the flushing will not allow people to increase their NAD+ levels high enough.
Normal human ageing shows decline in skin tissue NAD+ levels from ~4 mM at age 20, to ~3 at 40, ~2 at 60, and ~1 at 80 years in women, and perhaps worse (lower levels) in men.
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0042357
Figure 4.
Another important consideration the SA author brings up besides the 3 vitamins/supplements' effects on NAD+ levels is the NR markup. I recall CDXC charging $1,000/kg or $1/g of NR to Elysium. Other companies then sell say 125 mg x60 pills = 7.5 g for $40, a ~5x markup! Maybe CDXC could sell direct to consumer to cut out the middle man?
I remain long CDXC. I think this is another overreaction, and that NR will show to be an important neuroprotectant and anti-aging supplement/medicine.
Recent CDXC News
- ChromaDex’s NIAGEN® (Patented Nicotinamide Riboside, NR), the Most Efficient and High-Quality NAD+ Precursor, Featured in New Solgar® Cellular Nutrition Cellular Energy Supplement • Business Wire • 04/30/2024 12:32:00 PM
- ChromaDex Announces Nationwide Launch of Tru Niagen® at The Vitamin Shoppe® • Business Wire • 04/25/2024 12:34:00 PM
- ChromaDex to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024 • Business Wire • 04/24/2024 12:34:00 PM
- ChromaDex Announces Inaugural Major Grocery Debut of Tru Niagen® at Sprouts Farmers Market • Business Wire • 04/23/2024 12:32:00 PM
- ChromaDex Announces Tru Niagen® is Now Third-Party Verified Through the Alkemist Assured™ Transparency Program • Business Wire • 03/26/2024 12:32:00 PM
- ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 Results • Business Wire • 03/06/2024 09:04:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 09:02:29 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/06/2024 09:01:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/24/2024 02:00:40 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/24/2024 01:59:47 AM
- ChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024 • Business Wire • 02/21/2024 01:32:00 PM
- ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Monday, February 12, 2024 • Business Wire • 02/05/2024 01:32:00 PM
- ChromaDex to Present at the Lytham Partners 2024 Investor Select Conference • Business Wire • 01/26/2024 09:08:00 PM
- ChromaDex Supports the US Military with its Industry Leading NAD+ Supplement, Tru Niagen® • Business Wire • 12/20/2023 02:04:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/13/2023 09:00:16 PM
- Neurohacker Collective and ChromaDex Partner to Optimize Cellular Health with the Debut of Qualia NAD+ • PR Newswire (US) • 12/12/2023 03:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/04/2023 09:12:33 PM
- A Milestone Phase I Randomized, Double-Blind Clinical Trial Demonstrates High-Dose Niagen®, Patented Nicotinamide Riboside (NR), Supplementation Induces a Potent NAD+ Response and Is Associated With Mild Improvement in Parkinson's Disease (PD) • Business Wire • 11/30/2023 01:34:00 PM
- Newly Published Phase II Clinical Study Demonstrates that Supplementation with Niagen®, Patented Nicotinamide Riboside (NR), Elevates NAD+ Up to Fourfold, Improving Motor Coordination and Eye Movement in Ataxia Telangiectasia (AT) Patients • Business Wire • 11/15/2023 01:32:00 PM
- ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Tuesday, November 14, 2023 • Business Wire • 11/09/2023 01:32:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/08/2023 09:02:24 PM
- ChromaDex Corporation Reports Third Quarter 2023 Financial Results • Business Wire • 11/08/2023 09:02:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/08/2023 09:01:06 PM
- ChromaDex Debuts Clinical Strength Tru Niagen® Pro 1,000mg Featuring Niagen® (Patented Nicotinamide Riboside), One of the Most Efficient Nicotinamide Adenine Dinucleotide (NAD+) Boosters Available, to Consumers Nationwide • Business Wire • 11/01/2023 12:34:00 PM
- ChromaDex to Report Third Quarter 2023 Financial Results on Wednesday, November 8, 2023 • Business Wire • 10/31/2023 12:34:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM